Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors

Author(s)

Montor, Wagner Ricardo ^[1] ; Silva Escartin Salas, Andrei Ronaldo Oliveira ^[1] ; Machado de Melo, Fabiana Henriques ^[1]

Affiliation

^[1] Fac Ciencias Med Santa Casa Sao Paulo, Dept Ciencias Fisiol, Sao Paulo - Brazil

• Document type: Review article
• Source: Molecular Cancer; v. 17, FEB 19 2018.
• Web of Science Citations: 11

Abstract

Searching for targets that allow pharmacological inhibition of cell proliferation in over-proliferative states, such as cancer, leads us to finely understand the complex mechanisms orchestrating the perfect control of mitosis number, frequency and pace as well as the molecular arrangements that induce cells to enter functional quiescence and brings them back to cycling in specific conditions. Although the mechanisms regulating cell proliferation have been described several years ago, never before has so much light been shed over this machinery as during the last decade when therapy targets have been explored and molecules, either synthetic or in the form of antibodies with the potential of becoming cancer drugs were produced and adjusted for specific binding and function. Proteins containing tyrosine kinase domains, either membrane receptors or cytoplasmic molecules, plus the ones activated by those in downstream pathways, having tyrosine kinase domains or not, such as RAS which is a GTPase and serine/threonine kinases such as RAF, play crucial role in conducting proliferation information from cell surroundings to the nucleus where gene expression takes place. Tyrosine kinases phosphorylate tyrosine residues in an activating mode and are found in important growth factor receptors, such as for ligands from families collectively known as VEGF, PDGF and EGF, to name a few and in intracellular downstream molecules. They all play important roles in normal physiology and are commonly found mutated or overexpressed in neoplastic states. Our objective here is to present such kinases as druggable targets for cancer therapy, highlighting the ones for which the pharmacological arsenal is available, discussing specificity, resistance mechanisms and treatment alternatives in cases of resistance, plus listing potential targets that have not been successfully worked yet. (AU)

• FAPESP's process: 17/04352-0 - Contribution of the interaction between caveolin-1 and the enzymes GTP cyclohydrolase I and nitric oxide synthase along melanoma progression
• Grantee: Fabiana Henriques Machado de Melo
• Support Opportunities: Regular Research Grants